A longevity expert who studied people who live to 110 on how humanity and AI will master aging
Publishing timestamp: 2023-03-07 16:06:10
Summary
BioAge, a clinical stage biotech company, is using AI-discovered biomarkers and predictive analytics to develop treatments that target the molecular causes of aging. The company has raised $127 million in funding and is focused on addressing the fundamental problems of age, including loss of muscle strength and cognitive decline. BioAge takes a "human data first" approach to understanding aging and uses AI and machine learning to analyze molecular features of people who live the healthiest, longest lives. The company is developing drugs to treat specific diseases in the near term, but envisions a longer-term path similar to statins, where drugs based on aging biology are used to prevent blockbuster diseases of aging.
Sentiment: POSITIVE
Tickers: KVSA,
Keywords: business news, aging, biotechnology, biotech and pharmaceuticals, science, artificial intelligence, khosla ventures acquisition co, business, machine learning,